Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Phase 1/2 Completed 77 enrolled NS Pharma, Inc.

NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (post-ET MF)

Timeline

Start: 2011-06
Primary completion: 2020-04-22
Completion: 2020-04-22

Publications

Verstovsek S, Talpaz M, Ritchie E, Wadleigh M, Odenike O, Jamieson C, Stein B, Uno T, Mesa RA. A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis. Leukemia. 2017 Feb;31(2):393-402. doi: 10.1038/leu.2016.215. Epub 2016 Aug 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	NS-018	Small molecule	75 mg	Oral
Subject	NS-018	Small molecule	100 mg	Oral
Subject	NS-018	Small molecule	125 mg	Oral
Subject	NS-018	Small molecule	200 mg	Oral
Subject	NS-018	Small molecule	250 mg	Oral
Subject	NS-018	Small molecule	300 mg	Oral
Subject	NS-018	Small molecule	400 mg	Oral

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Summary

Timeline

Publications

Drugs

Indications